US equities
|
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
MU
$878.84
▼-5.63%
NVDA
$214.13
▼-1.43%
TSLA
$354.72
▼-2.13%
AAPL
$343.46
▲+0.43%
META
$709.33
▼-3.72%
MSFT
$529.05
▼-1.93%
SPCX
$146.03
▼-1.74%
AMD
$528.75
▼-5.95%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Propanc Biopharma, Inc. - Common Stock
(NQ:
PPCB
)
0.3420
+0.0005 (+0.15%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 16, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Propanc Biopharma, Inc. - Common Stock
< Previous
1
2
Next >
Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells
October 16, 2026
New Preclinical Findings Identify Potential Strategy to Remodel Resistant Tumor State & Restore Therapeutic Vulnerability
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer
October 14, 2026
Scientific Reports Paper Shows Synergistic Trypsinogen/Chymotrypsinogen A Combination (1:6) Inhibits Angiogenesis, Migration, Invasion and EMT While Delivering Significant Tumor Reduction in Orthotopic...
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
October 07, 2026
Preclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, differentiation-based mechanism with the clinical benchmark set by RASONQUE...
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results
September 29, 2026
Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015
September 22, 2026
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
September 16, 2026
New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to...
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
September 09, 2026
Open-label, two-part dose-escalation and dose-expansion study planned in up to 50 patients with advanced solid tumors across Australia
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
August 27, 2026
Differentiated Profile versus RAS-Targeted Approaches Including Revolution Medicines’ Daraxonrasib
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
August 18, 2026
Avance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
August 12, 2026
Contrasting Science with Revolution Medicines and Erasca
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
August 06, 2026
Accelerates Phase 1b First-in-Human Trial Timeline
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
August 05, 2026
Purchasing $500,000 within First 30 days Since Program Commencement
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
July 21, 2026
A Promising Strategy for Improving Production for Applications in Biotechnology Research
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
July 07, 2026
Sets out Shared Intent to Support Delivery of Propanc’s First-In-Human Clinical Trial for PRP
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
July 02, 2026
The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
June 16, 2026
Pre-production, Engineering Run and GMP Manufacture of PRP in 2026
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
June 11, 2026
Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of Metastatic Cancer from Solid Tumors
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
June 02, 2026
Dr. Juan Carlos Izpisúa Provides the UGR With the Keys to Science Against Ageing
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
May 20, 2026
Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
May 19, 2026
Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics Production
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
May 15, 2026
Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
May 13, 2026
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
April 17, 2026
From
Rosen Law Firm
Via
Business Wire
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
April 16, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
March 24, 2026
Fifth Agreement between Propanc & the Universities over a 17yr Period
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
March 12, 2026
Root-Cause Attack. Chemo Sensitization. Safer Profile.
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
March 10, 2026
A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
March 03, 2026
PRP May Outshine Traditional Therapies in a Booming $4.4 Billion Market
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
February 18, 2026
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
February 05, 2026
From
Propanc Biopharma, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
